Trial · NCT01367665
Results by group86
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 86
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Percentage of Participants Who Experienced Any Adverse Events (AEs), AEs Grade 3 or 4, AEs Leading to Drug Interruptions or Discontinuations and Any Serious Adverse Events (SAEs) | Vismodegib - Locally Advanced | Any AEs | 98.4 | percentage of participants | |
| Percentage of Participants Who Experienced Any Adverse Events (AEs), AEs Grade 3 or 4, AEs Leading to Drug Interruptions or Discontinuations and Any Serious Adverse Events (SAEs) | Vismodegib - Metastatic | Any AEs | 99.0 | percentage of participants | |
| Percentage of Participants Who Experienced Any Adverse Events (AEs), AEs Grade 3 or 4, AEs Leading to Drug Interruptions or Discontinuations and Any Serious Adverse Events (SAEs) | Vismodegib - Locally Advanced | Any AEs with maximum severity of Grade 3 or 4 | 43.4 | percentage of participants | |
| Percentage of Participants Who Experienced Any Adverse Events (AEs), AEs Grade 3 or 4, AEs Leading to Drug Interruptions or Discontinuations and Any Serious Adverse Events (SAEs) | Vismodegib - Metastatic | Any AEs with maximum severity of Grade 3 or 4 | 52.1 | percentage of participants | |
| Percentage of Participants Who Experienced Any Adverse Events (AEs), AEs Grade 3 or 4, AEs Leading to Drug Interruptions or Discontinuations and Any Serious Adverse Events (SAEs) | Vismodegib - Locally Advanced | Any Serious AEs | 24.3 | percentage of participants | |
| Percentage of Participants Who Experienced Any Adverse Events (AEs), AEs Grade 3 or 4, AEs Leading to Drug Interruptions or Discontinuations and Any Serious Adverse Events (SAEs) | Vismodegib - Metastatic | Any Serious AEs | 32.3 | percentage of participants | |
| Percentage of Participants Who Experienced Any Adverse Events (AEs), AEs Grade 3 or 4, AEs Leading to Drug Interruptions or Discontinuations and Any Serious Adverse Events (SAEs) | Vismodegib - Locally Advanced | Any AEs leading to study drug interruption | 40.5 | percentage of participants | |
| Percentage of Participants Who Experienced Any Adverse Events (AEs), AEs Grade 3 or 4, AEs Leading to Drug Interruptions or Discontinuations and Any Serious Adverse Events (SAEs) | Vismodegib - Metastatic | Any AEs leading to study drug interruption | 35.4 | percentage of participants | |
| Percentage of Participants Who Experienced Any Adverse Events (AEs), AEs Grade 3 or 4, AEs Leading to Drug Interruptions or Discontinuations and Any Serious Adverse Events (SAEs) | Vismodegib - Locally Advanced | Any AEs leading to study drug discontinuation | 33.8 | percentage of participants | |
| Percentage of Participants Who Experienced Any Adverse Events (AEs), AEs Grade 3 or 4, AEs Leading to Drug Interruptions or Discontinuations and Any Serious Adverse Events (SAEs) | Vismodegib - Metastatic | Any AEs leading to study drug discontinuation | 17.7 | percentage of participants | |
| Percentage of Participants Who Died Due to Adverse Events, Disease Progression or Other Reasons | Vismodegib - Locally Advanced | Adverse Event | 6.1 | percentage of participants | |
| Percentage of Participants Who Died Due to Adverse Events, Disease Progression or Other Reasons | Vismodegib - Metastatic | Adverse Event | 6.3 | percentage of participants | |
| Percentage of Participants Who Died Due to Adverse Events, Disease Progression or Other Reasons | Vismodegib - Locally Advanced | Disease Progression | 1.9 | percentage of participants | |
| Percentage of Participants Who Died Due to Adverse Events, Disease Progression or Other Reasons | Vismodegib - Metastatic | Disease Progression | 13.5 | percentage of participants | |
| Percentage of Participants Who Died Due to Adverse Events, Disease Progression or Other Reasons | Vismodegib - Locally Advanced | Other | 1.3 | percentage of participants | |
| Percentage of Participants Who Died Due to Adverse Events, Disease Progression or Other Reasons | Vismodegib - Metastatic | Other | 0 | percentage of participants | |
| Percentage of Participants Who Report a Shift in NCI CTCAE Grades to 3/4 in Hematology and Biochemistry Laboratory Parameters | Vismodegib - Locally Advanced | Hemoglobin (High) | 0.1 | percentage of participants | |
| Percentage of Participants Who Report a Shift in NCI CTCAE Grades to 3/4 in Hematology and Biochemistry Laboratory Parameters | Vismodegib - Metastatic | Hemoglobin (High) | 0 | percentage of participants | |
| Percentage of Participants Who Report a Shift in NCI CTCAE Grades to 3/4 in Hematology and Biochemistry Laboratory Parameters | Vismodegib - Locally Advanced | Hemoglobin (Low) | 1.3 | percentage of participants | |
| Percentage of Participants Who Report a Shift in NCI CTCAE Grades to 3/4 in Hematology and Biochemistry Laboratory Parameters | Vismodegib - Metastatic | Hemoglobin (Low) | 2.1 | percentage of participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01367665/results